Thymic neuroendocrine tumor
Learn about Thymic neuroendocrine tumor, its reported features, relevant specialists, and questions to discuss at a medical consultation.
The sources compiled here do not cover: diagnosis, treatment, prevention, prognosis, prevalence. Ask the treating doctor about these.
What it is
From: Orphanet
A rare, malignant, primary thymic neoplasm originating from neuroendocrine cells, presenting as a mass within the anterior mediastinum. Patients typically present with nonspecific symptoms, such as chest pain, cough, shortness of breath, or in some cases, superior vena cava syndrome, although patients could be asymptomatic during the early stages or present with multiple endocrine neoplasia type I. Ectopic production of ACTH and serotonin can lead to Cushing syndrome and carcinoid syndrome, respectively.
Reported clinical features and what the terms mean
The following findings are associated with this condition in Orphanet. They are not a checklist for diagnosing yourself, and they do not all occur in every affected person. Some are examination, imaging or laboratory findings that cannot be recognised at home.
The frequency labels describe how often a finding was reported among people with the condition in the source. They do not give the chance that a person with that symptom has the condition. Definitions below reproduce HPO terminology; they explain the term, not the likely severity in an individual.
- Abnormal mediastinum morphology · Very frequent (99-80%)
- Any structural anomaly of the central compartment of the thoracic cavity.
- Mediastinal lymphadenopathy · Very frequent (99-80%)
- Swelling of lymph nodes within the mediastinum, the central compartment of the thoracic cavities that contains the heart and the great vessels, the esophagus, and trachea and other structures including lymph nodes.
- Neoplasm of the thymus · Obligate (100%)
- A tumor (abnormal growth of tissue) of the thymus.
- Neuroendocrine neoplasm · Obligate (100%)
- A tumor that originates from a neuroendocrine cell.
- Abnormal breath sound · Frequent (79-30%)
- An anomalous (adventitious) sound produced by the breathing process.
- Abnormal vena cava morphology · Frequent (79-30%)
- An abnormality of the structure of the veins that return deoxygenated blood from the body into the heart, i.e., the superior vena cava and the inferior vena cava.
- Carcinoid tumor · Frequent (79-30%)
- A tumor formed from the endocrine (argentaffin) cells of the mucosal lining of a variety of organs including the stomach and intestine. These cells are from neuroectodermal origin.
- Chest pain · Frequent (79-30%)
- An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the chest.
- Chronic noninfectious lymphadenopathy · Frequent (79-30%)
- A chronic form of lymphadenopathy that is not related to infection.
- Cough · Frequent (79-30%)
- A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation.
- Increased circulating ACTH level · Frequent (79-30%)
- An abnormal increased in the concentration of corticotropin, also known as adrenocorticotropic hormone (ACTH), in the blood.
- Increased circulating cortisol level · Frequent (79-30%)
- Overproduction of the hormone of cortisol by the adrenal cortex, resulting in a characteristic combination of clinical symptoms termed Cushing syndrome, with truncal obesity, a round, full face, striae atrophicae and acne, muscle weakness, and other features.
- Neoplasm of the endocrine system · Frequent (79-30%)
- A tumor (abnormal growth of tissue) of the endocrine system.
- Prominent veins on trunk · Frequent (79-30%)
- Prominent thoracic and abdominal veins.
Other findings in the same source
From: Orphanet
Additional reported features include Weight loss (Frequent (79-30%)); Calcium nephrolithiasis (Occasional (29-5%)); Hypercalcemia (Occasional (29-5%)); Increased circulating prolactin concentration (Occasional (29-5%)); Osteopenia (Occasional (29-5%)); Pancreatic islet cell adenoma (Occasional (29-5%)); Pituitary adenoma (Occasional (29-5%)); Pituitary null cell adenoma (Occasional (29-5%)); Pituitary prolactin cell adenoma (Occasional (29-5%)); Primary hyperparathyroidism (Occasional (29-5%)). This is a selected summary, not a complete description of the condition.
When it may begin
From: Orphanet
Adult; Elderly
Which doctor should you see?
The suggested department for discussing Thymic neuroendocrine tumor is Oncology, with a oncologist and relevant organ specialist as the relevant type of clinician. General physician / Family Medicine; paediatrician for children. Referral depends on symptoms.
Additional services that may be relevant, depending on the findings, include: Relevant organ specialist / Surgical Oncology as indicated.
This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.
How to prepare for an assessment
Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.
Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.
- Has the exact tumour type been confirmed, and is staging relevant?
- What is the goal of each proposed treatment option?
- How will side effects, daily function and supportive care be addressed?
Treatment discussions and follow-up
The material gathered for this draft does not provide a complete condition-specific treatment pathway for Thymic neuroendocrine tumor. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.
Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.
The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.
When to seek emergency help
Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.
Oncology is not listed separately on The Doctor Index; the nearest speciality is medical oncology. Every profile shows the doctor’s registration and what has been checked.
Sources
- Orphanet — Thymic neuroendocrine tumor — Orphadata Science, CC BY 4.0
- Human Phenotype Ontology Consortium — terminology definitions — HPO licence; definitions reproduced without alteration
- Government of India — Emergency Response Support System — Official reference for India emergency number
Source: MedlinePlus, National Library of Medicine. Orphadata Science: Free access data from Orphanet. © INSERM 1999; July 2026 data, CC BY 4.0. This product uses the Human Phenotype Ontology (hp/releases/2026-09-01). Only sources listed for this article apply. Source material has been selected and arranged; HPO definitions are reproduced without alteration. No source organisation endorses this compilation. Köhler S et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Research 2014;42(D1):D966–D974. doi:10.1093/nar/gkt1026.
General information, not advice about your situation. Errors can be reported through the corrections process. Reference TDI-C-2321.